10 July 2025 in Experimental & Molecular Medicine
Proximity labeling (PL) techniques have advanced neuroscience by revealing the molecular interactions that govern neural circuits. From foundational tools such as BioID and APEX to recent innovations such as TurboID and light-activated systems, PL enables precise mapping of protein–protein interactions within living cells. Recent applications have identified dynamic protein networks in synaptic remodeling, calcium-dependent signaling and disease states, such as neurodegenerative and psychiatric disorders. These studies not only deepen our comprehension of the molecular architecture of the brain but also uncover novel therapeutic targets. By integrating PL with cutting-edge multi-omics strategies and advanced imaging technologies, researchers can decode the intricate interplay between structural and functional neural networks. As PL technologies continue to evolve, they bridge molecular and cellular neuroscience, offering a useful framework for unraveling the complexity of brain networks. Here, in this Review, we underscore the potential of PL in neuroscience, furthering our understanding of the molecular basis of neural connectivity in both health and disease.
24 July 2025 in Scientific Reports
Sex is a key piece of patient information but is often not actively considered in drug use. This is partly due to the lack of molecular evidence at the gene expression level beyond sex chromosomes and sex hormones. We aim to investigate how sex differences in tissue-specific gene expression relate to FDA-approved drugs using the latest database of The Genotype-Tissue Expression (GTEx) V10. Our analysis reveals that 91.4% of FDA-approved drug target genes exhibit sex-differential expression in at least one tissue. The tissues with the most pronounced sex differences include subcutaneous adipose tissue, skeletal muscle, and the pituitary gland, while sex differences are less pronounced in the liver, other brain regions, and the spleen. Sex-differential disease-related genes include those associated with obesity (PPARG, INSR), cancer (FGFR1, CD22), and immunity (IL6R, IL3RA). Based on our findings, we advocate for a policy shift that integrates sex-based molecular data into preclinical studies, drug development, and clinical practices. This paradigm aligns biomedical research with precision medicine, mitigates drug-related risks, and promotes equitable healthcare outcomes.